Business Context and Reporting Period
This Form 6-K is filed by Midatech Pharma PLC (noted as Biodexa Pharmaceuticals Plc in metadata) for the month of April 2019. The filing addresses the status of the Company's American Depositary Shares (ADS) regarding NASDAQ listing requirements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On May 1, 2018, the Company was notified of non-compliance with NASDAQ Listing Rule 5550(a)(2) due to failing to maintain a minimum bid price of $1.00 for 30 consecutive business days. As of April 23, 2019, the Company received confirmation that the closing bid price had been at or above $1.00 for the 10 consecutive business days from April 8 to April 22, 2019.
Outlook and Management Commentary
Management confirms that the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2) and that the matter is now closed. No forward-looking guidance, risk factors, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the current trading price of Midatech Pharma PLC ADS to ensure continued compliance with the $1.00 minimum bid requirement.
- Confirm the Company's status on the NASDAQ exchange to ensure no new delisting notices have been issued.
- Review subsequent filings for any financial updates, as this Form 6-K contains no financial data.